218 results on '"Woelber, L."'
Search Results
2. Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
3. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
4. The use of colposcopy for triage in HPV-positive women aged 65 years and older
5. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
6. Das Vulvakarzinomrezidiv: eine besondere Herausforderung
7. Colposcopic results in women aged 65 years and older who present with normal cytology and positive HPV results
8. Risiko für eine pelvine Metastasierung und Stellenwert der pelvinen Lymphonodektomie bei Patientinnen mit nodal-positivem Vulvakarzinom – Ergebnisse der AGO-VOP.2/QS Vulva Studie
9. 533P Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)
10. 561P When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study
11. 604P T cell density and immune phenotypes at the invasive margin correlate with prognosis in epithelial vulvar cancer
12. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
13. 725P Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
14. Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study
15. EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
16. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer
17. Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
18. Rezidivtherapie des Ovarialkarzinoms: Systemische und operative Optionen
19. BIRC2 amplification in squamous cell carcinomas of the uterine cervix
20. LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
21. Sexual activity and function in patients with gynecological malignancies after completed treatment: ID 303
22. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer:Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
23. Importance of pelvic Lymphonodectomy in Squamous Cell Carcinoma of the Vulva (VSCC) Subgroup Analysis of the AGO-CaRE-1 Study
24. The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study
25. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
26. 149 Pelvic lymphadenectomy in vulvar squamous-cell cancer- a monocentric study of the relation between lymph-node involvement of groin and pelvis at the university medical center Hamburg
27. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome
28. Role of pelvic lymph node resection in vulvar cancer – a subset analysis of the AGO-CaRE-1 study
29. Präliminäre Ergebnisse der Implementierung des “Enhanced Recovery After Surgery” (ERAS) Programms in der gynäkologischen Onkologie am Universitätsklinikum Hamburg - Eppendorf (UKE)
30. The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study
31. LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
32. Bedeutung der pelvinen Lymphonodektomie beim Plattenepithelkarzinom der Vulva (VSCC) – Subgruppenanalyse der AGO-CaRE-1 Studie
33. Surgical management of peritoneal carcinomatosis in ovarian cancer
34. Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer
35. Genomic characterization of vulvar squamous cell carcinoma
36. Whole exome sequencing of vulvar squamous cell carcinoma and corresponding normal tissue
37. Correlation of isotope count with sentinel node positivity in vulvar cancer
38. Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial
39. European society of gynaecological oncology guidelines for the management of patients with Vulvar cancer
40. The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial
41. Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015
42. Loss of BRCA1 promotor hypermethylation in recurrent high grade ovarian cancer
43. Patterns of distant metastases in vulvar cancer
44. E-Cadherin-Fragmente als potenzielle Mediatoren für peritoneale Metastasierung des epithelialen Ovarialkarzinoms
45. 980P - Genomic characterization of vulvar squamous cell carcinoma
46. 964P - Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer
47. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study
48. Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri
49. AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer
50. Outcome parameters in node-negative vulvar cancer - subset analysis of the AGO CaRE-1 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.